What It Is
MOTS-c is an unusually short, 16-amino-acid peptide notable for where it comes from: it is encoded by mitochondrial DNA itself, within a region called MT-RNR1 that was previously thought to only produce ribosomal RNA. It belongs to a small, newly described class called mitochondrial-derived peptides, alongside a related molecule called humanin.[1]
It was first described in a 2015 study as a regulator of metabolic homeostasis in mice, and research interest since has focused on metabolism, exercise physiology, and cellular energy signaling rather than any established medical use.
How It Works
MOTS-c is proposed to act as a messenger between mitochondria and the rest of the cell, including the nucleus. In animal and cell studies it activates AMPK, a central cellular energy-sensing enzyme, and interacts with folate and purine metabolism pathways tied to glucose handling.[1] Under metabolic stress, MOTS-c has been shown to move into the cell nucleus and influence gene expression, a process researchers call mitochondrial-to-nuclear retrograde signaling.
This is a genuinely novel signaling mechanism, but it is also complex and only partly mapped — a plausible mechanism in mice and cells is not the same as a proven effect in people.
What the Research Shows
Detailed findings come from mouse and cell studies. In diet-induced-obesity mouse models, MOTS-c administration improved insulin-sensitivity measures and reduced weight gain.[1] A later study described MOTS-c as an exercise-induced regulator linked to age-related physical decline and muscle function in mice, with supporting human observations correlating circulating MOTS-c with age and exercise.[3]
These observational measurements are not trials of administering MOTS-c. In its 2026 review, FDA identified no clinical studies or human exposure data for MOTS-c free base or acetate by any route.[20]
The Mitochondrial and Exercise-Mimetic Angle
MOTS-c's research niche sits squarely at the intersection of mitochondrial biology and exercise physiology. It is often discussed as an "exercise mimetic" candidate because it appears to link physical activity to metabolic gene expression and muscle maintenance in aging mice.
This research angle has fed into online longevity and performance marketing, but claims that MOTS-c administration improves human athletic performance, slows aging, or treats metabolic disease go well beyond what current mouse-and-cell evidence supports.
Safety & Side Effects
There is no established human side-effect profile, contraindication set, or long-term safety record for exogenous MOTS-c. FDA found no human exposure data, no clinical pharmacokinetic studies, and no nonclinical toxicity studies adequate to inform its nominated clinical uses.[20]
FDA also identified unresolved aggregation, impurity, and immunogenicity concerns for this endogenous 16-amino-acid peptide. Products sold online as research-grade MOTS-c add identity, purity, concentration, and sterility uncertainty to the underlying absence of human safety evidence.[21]
Regulatory Status
MOTS-c has no FDA approval, approved indication, or approved human dosage.[4] At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA evaluated MOTS-c free base and acetate for obesity and osteoporosis.[19] FDA's briefing proposed not adding either substance to the 503A Bulks List because of poor characterization and the absence of human safety or effectiveness information.[20]
The proposal is part of an advisory process, not an approval. No online, compounded, or research product has regulator-reviewed labeling that defines safe human use.